Cardiología y enfermedades cardiovasculares. Varios autores

28. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131(1):34-42. https://doi.org/10.1161/CIRCULATIONAHA.114.013255

29. De Denus S, O’Meara E, Desai AS, et al. Spironolactone metabolites in TOPCAT: new insights into regional variation. N Engl J Med. 2017;376(17): 1690-1692. doi: 10.1056/NEJMc1612601

30. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. The Lancet. 2012;380(9851):1387-1395. https://doi.org/10.1016/S0140-6736(12)61227-6

31. Solomon SD, McMurray JJ, Anand IS, et al. Angiotensin: neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17): 1609-1620. DOI: 10.1056/NEJMoa1908655